Indoco Remedies passes US FDA inspection at its Chhatrapati Sambhaji Nagar facility without any issues, indicating a successful pre-approval assessment and compliance with regulatory standards.

Indoco Remedies experiences a 3.86% share increase after passing the US FDA pre-approval inspection with no significant issues, trading at ₹209.95 per share. Despite an expanded Q3 net loss of ₹29.8 crore and a revenue uptick of 8.5%, EBITDA nearly tripled to ₹31.5 crore.

Indoco Remedies' testing facility successfully passed the FDA pre-approval inspection, demonstrating no areas for improvement. This is a significant milestone for the company in maintaining high-quality standards.

Indoco Remedies has successfully passed the recent US FDA inspection at their Aurangabad facility with no issues found, indicating a favorable position for exporting products to the U.S. market.